CARDIFF ONCOLOGY INC

Company Overview

Cardiff Oncology is a clinical‑stage biotechnology company developing onvansertib, an oral PLK1 inhibitor designed to be combined with standard‑of‑care chemotherapies and targeted agents across high‑need cancers—primarily RAS‑mutated metastatic colorectal cancer (mCRC) and investigator‑initiated programs in mPDAC, SCLC and TNBC. The company completed enrollment in the randomized Phase 2 CRDF‑1004 (~90 evaluable patients) and reported substantially higher objective response rates in onvansertib arms (pooled ~57%, 64% at 30 mg) versus 33% for SoC, supporting a potential registrational Phase 3 and an FDA‑accepted seamless ORR interim pathway. Cardiff is small (33 employees), relies on third‑party manufacturing and Pfizer Ignite for trial execution, holds a growing IP estate (57 issued/57 pending) including recent U.S. patents (Nov 2024, June 2025), and remains development‑stage with limited revenue, rising R&D spend, and a cash runway currently projected into Q1 2027.

Executive Compensation Practices

Compensation at Cardiff is likely driven heavily by clinical and regulatory milestones (CRDF‑1004 readouts, FDA interactions, and the decision to start a Phase 3), plus IP and financing events; management already cites increased stock‑based compensation in SG&A. As a small oncology biotech with rising R&D burn ($36.9M in 2024; higher in 2025 YTD) and an accumulated deficit, packages typically emphasize equity (options/RSUs) and milestone‑linked bonuses to conserve cash and align executives with long‑term value creation. Recent hiring (including a new CMO) and the company’s dependence on successful trial outcomes and capital raises (e.g., Dec 2024 registered direct offering) also support retention‑focused equity grants and potential one‑time awards tied to patent issuances or successful financing/approval milestones.

Insider Trading Considerations

Insider trading activity for Cardiff will likely cluster around discrete binary catalysts: clinical data releases (CRDF‑1004 readouts and interim ORR updates), FDA feedback/filing milestones, patent issuances, and financing transactions—each can be material and move the stock. Expect common patterns for small biotechs: executives receiving equity grants then exercising or selling to cover taxes/liquidity, and occasional director/officer sales tied to financing windows (the Dec 2024 registered direct offering is a recent example); conversely, insider buys shortly before positive readouts can signal confidence. Regulatory constraints (SEC Rule 10b‑5, Reg FD), company blackout periods around clinical disclosures, and the use of 10b5‑1 trading plans are important — watch Form 4 filings closely around trial enrollment completion, patent announcements (Nov 2024/June 2025), and any Phase‑3 decision announcements as primary triggers of insider transactions.